4D Molecular Therapeutics Inc
FDMT7.970USD
-0.130-1.60%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
372.77MMarket Cap
LossP/E TTM
More Details of 4D Molecular Therapeutics Inc Company
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.
4D Molecular Therapeutics Inc Info
Ticker SymbolFDMT
Company name4D Molecular Therapeutics Inc
IPO dateDec 11, 2020
CEOKirn (David)
Number of employees227
Security typeOrdinary Share
Fiscal year-endDec 11
Address5858 Horton Street #455
CityEMERYVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94608
Phone15105052680
Websitehttps://4dmoleculartherapeutics.com/
Ticker SymbolFDMT
IPO dateDec 11, 2020
CEOKirn (David)
Company Executives of 4D Molecular Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. David Kirn, M.D.
Dr. David Kirn, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.66M
-0.02%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
100.00K
--
Dr. Fariborz (Fred) Kamal, Ph.D.
Dr. Fariborz (Fred) Kamal, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
5.94K
--
Mr. Kristian F. Humer
Mr. Kristian F. Humer
Chief Financial Officer and Principal Financial Officer
Chief Financial Officer and Principal Financial Officer
--
--
Dr. Scott Bizily, J.D., Ph.D.
Dr. Scott Bizily, J.D., Ph.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Dhaval Desai, Pharm.D.
Dr. Dhaval Desai, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Charles P. Theuer, M.D., Ph.D.
Dr. Charles P. Theuer, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Nancy Miller-Rich
Ms. Nancy Miller-Rich
Independent Director
Independent Director
--
--
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Simms
Mr. Christopher (Chris) Simms
Chief Commercial Officer
Chief Commercial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. David Kirn, M.D.
Dr. David Kirn, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.66M
-0.02%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
100.00K
--
Dr. Fariborz (Fred) Kamal, Ph.D.
Dr. Fariborz (Fred) Kamal, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
5.94K
--
Mr. Kristian F. Humer
Mr. Kristian F. Humer
Chief Financial Officer and Principal Financial Officer
Chief Financial Officer and Principal Financial Officer
--
--
Dr. Scott Bizily, J.D., Ph.D.
Dr. Scott Bizily, J.D., Ph.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Dhaval Desai, Pharm.D.
Dr. Dhaval Desai, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
15.00K
0.00%
Netherlands
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BVF Partners L.P.
8.10%
RA Capital Management, LP
7.99%
Goldman Sachs & Company, Inc.
6.49%
Novo Holdings A/S
5.56%
BlackRock Institutional Trust Company, N.A.
5.27%
Other
66.60%
Shareholders
Shareholders
Proportion
BVF Partners L.P.
8.10%
RA Capital Management, LP
7.99%
Goldman Sachs & Company, Inc.
6.49%
Novo Holdings A/S
5.56%
BlackRock Institutional Trust Company, N.A.
5.27%
Other
66.60%
Shareholder Types
Shareholders
Proportion
Investment Advisor
16.89%
Hedge Fund
15.45%
Investment Advisor/Hedge Fund
14.93%
Venture Capital
13.78%
Research Firm
10.70%
Individual Investor
3.24%
Sovereign Wealth Fund
0.09%
Bank and Trust
0.09%
Pension Fund
0.07%
Other
24.76%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
341
40.63M
123.08%
--
2025Q3
346
40.63M
123.81%
+1.46K
2025Q2
352
40.62M
126.04%
-3.84M
2025Q1
351
44.47M
124.74%
-13.29M
2024Q4
351
47.77M
132.92%
-5.15M
2024Q3
343
58.58M
121.63%
+168.00K
2024Q2
333
58.21M
117.71%
+835.97K
2024Q1
317
57.48M
92.47%
+10.17M
2023Q4
276
43.57M
106.83%
+555.36K
2023Q3
265
42.98M
107.55%
+729.10K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BVF Partners L.P.
4.63M
9.91%
+68.00K
+1.49%
Jun 30, 2025
RA Capital Management, LP
4.56M
9.77%
--
--
Jun 30, 2025
Goldman Sachs & Company, Inc.
3.74M
8.01%
-7.99K
-0.21%
Jun 30, 2025
Novo Holdings A/S
2.00M
4.28%
+50.00K
+2.56%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.12M
6.67%
-415.30K
-11.76%
Jun 30, 2025
The Vanguard Group, Inc.
2.74M
5.86%
-20.82K
-0.75%
Jun 30, 2025
Janus Henderson Investors
1.75M
3.76%
-137.53K
-7.27%
Jun 30, 2025
Kirn (David)
1.66M
3.55%
-360.00
-0.02%
Apr 24, 2025
Federated MDTA LLC
1.65M
3.54%
+411.45K
+33.10%
Jun 30, 2025
Millennium Management LLC
1.48M
3.18%
-150.26K
-9.20%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Federated Hermes MDT Small Cap Core ETF
0.43%
Harbor Human Capital Factor US Small Cap ETF
0.1%
iShares Micro-Cap ETF
0.09%
iShares Health Innovation Active ETF
0.08%
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.05%
iShares Biotechnology ETF
0.04%
Avantis US Small Cap Equity ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
iShares Russell 2000 Value ETF
0.03%
View more
Federated Hermes MDT Small Cap Core ETF
Proportion0.43%
Harbor Human Capital Factor US Small Cap ETF
Proportion0.1%
iShares Micro-Cap ETF
Proportion0.09%
iShares Health Innovation Active ETF
Proportion0.08%
ProShares Ultra Nasdaq Biotechnology
Proportion0.07%
Invesco Nasdaq Biotechnology ETF
Proportion0.05%
iShares Biotechnology ETF
Proportion0.04%
Avantis US Small Cap Equity ETF
Proportion0.04%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of 4D Molecular Therapeutics Inc?
The top five shareholders of 4D Molecular Therapeutics Inc are:
BVF Partners L.P. holds 4.63M shares, accounting for 9.91% of the total shares.
RA Capital Management, LP holds 4.56M shares, accounting for 9.77% of the total shares.
Goldman Sachs & Company, Inc. holds 3.74M shares, accounting for 8.01% of the total shares.
Novo Holdings A/S holds 2.00M shares, accounting for 4.28% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.12M shares, accounting for 6.67% of the total shares.
BVF Partners L.P. holds 4.63M shares, accounting for 9.91% of the total shares.
RA Capital Management, LP holds 4.56M shares, accounting for 9.77% of the total shares.
Goldman Sachs & Company, Inc. holds 3.74M shares, accounting for 8.01% of the total shares.
Novo Holdings A/S holds 2.00M shares, accounting for 4.28% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.12M shares, accounting for 6.67% of the total shares.
What are the top three shareholder types of 4D Molecular Therapeutics Inc?
The top three shareholder types of 4D Molecular Therapeutics Inc are:
BVF Partners L.P.
RA Capital Management, LP
Goldman Sachs & Company, Inc.
BVF Partners L.P.
RA Capital Management, LP
Goldman Sachs & Company, Inc.
How many institutions hold shares of 4D Molecular Therapeutics Inc (FDMT)?
As of 2025Q4, 341 institutions hold shares of 4D Molecular Therapeutics Inc, with a combined market value of approximately 40.63M, accounting for 123.08% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.73%.
What is the biggest source of revenue for 4D Molecular Therapeutics Inc?
In FY2025Q2, the -- business generated the highest revenue for 4D Molecular Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
